{
    "nct_id": "NCT04184869",
    "official_title": "A Multi-Center, Open-Label, Extension Study to Allow Continued Treatment of Patients Who Have Participated in Spectrum-Sponsored Clinical Studies With Belinostat",
    "inclusion_criteria": "* Patient has participated in, and completed, a Spectrum-sponsored clinical study with belinostat and did not meet the treatment discontinuation criteria in the study\n* Investigator considers this extended belinostat treatment is appropriate for patient, and patient is suitable for the treatment\n* Patient agrees to continue belinostat treatment as defined in the original clinical study protocol\n* Patient must be willing to give written Informed Consent and must be able to adhere to dosing and visit schedules and meet study requirements\n* Patient is willing to practice two forms of contraception, one of which must be a barrier method, from study entry until at least 30 days after the last dose of the study drug\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patient has an active uncontrolled infection, underlying medical condition, or other serious illness that would impair the ability of the patient to receive belinostat benefit\n* Patient is receiving any other treatment modalities including investigational products for their malignancy\n* Patient has any medical or non-medical condition that may not be suitable for belinostat treatment, as determined by the investigator and according to the US package insert\n* Patient is pregnant or is breastfeeding",
    "miscellaneous_criteria": ""
}